1. Home
  2. ADIL vs LIXT Comparison

ADIL vs LIXT Comparison

Compare ADIL & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$0.29

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.11

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADIL
LIXT
Founded
2010
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
25.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ADIL
LIXT
Price
$0.29
$4.11
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.50
N/A
AVG Volume (30 Days)
344.9K
88.8K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.64
52 Week High
$1.30
$6.26

Technical Indicators

Market Signals
Indicator
ADIL
LIXT
Relative Strength Index (RSI) 39.05 44.10
Support Level $0.30 $4.01
Resistance Level $0.32 $4.40
Average True Range (ATR) 0.02 0.39
MACD 0.00 -0.00
Stochastic Oscillator 23.20 40.94

Price Performance

Historical Comparison
ADIL
LIXT

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: